Login to Your Account

IBD candidate to clinic next year

Planting the stake: Landos series A hauls down $10M for LANCL2 pathway effort

By Randy Osborne
Staff Writer

Thursday, September 21, 2017

Josep Bassaganya-Riera, president and CEO of Landos Biopharma Inc., told BioWorld that the firm's lead compound, BT-11, in mouse models is "acting as a double-barrel shotgun" against inflammatory bowel disease (IBD), in both Crohn's disease and ulcerative colitis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription